Imunon Inc IMNN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMNN is a good fit for your portfolio.
News
-
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
-
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
-
IMUNON Reports Compliance with Nasdaq Listing Requirements
-
IMUNON Reports 2023 Financial Results and Provides Business Update
-
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
-
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
-
IMUNON Files IND Application to Begin Human Testing of IMNN-101
-
IMUNON Announces Leadership Change
Trading Information
- Previous Close Price
- $1.44
- Day Range
- $1.38–1.48
- 52-Week Range
- $0.48–2.00
- Bid/Ask
- $1.37 / $1.49
- Market Cap
- $13.54 Mil
- Volume/Avg
- 49,331 / 231,498
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body’s immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.imunon.com
Valuation
|
Metric
|
IMNN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IMNN
Financial Strength
|
Metric
|
IMNN
|
|---|---|
Quick Ratio | 2.12 |
Current Ratio | 2.47 |
Interest Coverage | −108.20 |
Quick Ratio
IMNN
Profitability
|
Metric
|
IMNN
|
|---|---|
Return on Assets (Normalized) | −57.46% |
Return on Equity (Normalized) | −85.12% |
Return on Invested Capital (Normalized) | −74.67% |
Return on Assets
IMNN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rtzlhwdfvp | Ypz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vxwhgjgjr | Djwhqp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rwjrcsfq | Ykyclng | $97.8 Bil | |
MRNA
| Moderna Inc | Pqvrsmwh | Vfkht | $41.3 Bil | |
ARGX
| argenx SE ADR | Jldrqrky | Xyn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lypztft | Bjs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zkhplchw | Zkngg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mgnlptmzv | Zvxxrz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Llgjxxcdkb | Gfllb | $12.5 Bil | |
INCY
| Incyte Corp | Jhfkbrwh | Mffhz | $11.6 Bil |